Caixin News Agency, July 25, today 1 new shares for subscription, for the GEM Jiang Bolong; 3 new shares listed, respectively, for the SZSE Chuhuan technology, Shanghai main board Jintuo shares, Science and Technology Board of the Yifang biological.
Today's IPO
Jiang Bo Long is a leading domestic semiconductor storage company, mainly engaged in the research and development, design and sales of Flash and DRAM memory, the products mainly include embedded storage, SSD, mobile storage and memory sticks. According to Omdia data, from January to September 2021, the company's Lexar memory cards ranked second in global market share, and Lexar flash drives (USB flash drives) ranked third in global market share.
The company will realize operating revenue of 5.721 billion yuan, 7.276 billion yuan and 9.749 billion yuan in 2019-2021, respectively; and net profit of 128 million yuan, 276 million yuan and 1.013 billion yuan. The company expects operating income in the first half of 2022 to fall 11.35% to 3.80% year-on-year; net profit attributable to mother declined 47.08% to 39.73% year-on-year.
Today's listing of new shares
Chu Huan Technology is a leading manufacturer of special equipment for environmental protection in the treatment of waste gas and odor in China. The service industry involves municipal sewage treatment plant, kitchen waste treatment plant, petroleum refining, pharmaceutical and chemical industry, etc., the service of more than 800 enterprises, completed the national contract project case more than 1700.
The company's revenue from 2019-2021 is 258 million, 401 million, 587 million; net profit is 31.6 million, 74.15 million, 84.21 million. The company expects revenue for the first half of 2022 to increase by 11.65% to 35.92% year-on-year, net profit is expected to increase by 10.78% to 33.89% year-on-year, and non-deductible net profit is expected to increase by 11.46% to 34.80% year-on-year.
Jintuo is a leading manufacturer of aluminum alloy precision die castings in China. The company has formed a diversified product structure with automotive parts as the main focus, as well as smart home parts, industrial automation and robot parts, and information transmission equipment parts.
The company will realize operating revenues of 713 million yuan, 703 million yuan and 916 million yuan; net profit of 60 million yuan, 83 million yuan and 82 million yuan in 2019-2021, respectively.
Yifang Bio is an international innovative pharmaceutical company focusing on oncology and metabolic drugs. It has independently developed a series of innovative targeted drugs with patent protection, covering solid tumors such as non-small cell lung cancer, breast cancer, colorectal cancer, as well as metabolic diseases such as hyperuricemia and gout. The company's core product pipeline is independently developed and has global intellectual property rights, and has realized business cooperation with well-known domestic and international pharmaceutical companies such as Beda Pharmaceuticals, Pfizer, and Merck Sharp & Dohme.
It is worth noting that the company's products have not yet realized sales revenue and are in a loss-making status. The company's net profit in 2019-2021 will be -94.9859 million yuan, -1.053 billion yuan and -358 million yuan, respectively, with an accumulated loss of more than 1.5 billion yuan in the past three years.
For more real-time financial news, feel free to follow us.